Welcome to our dedicated page for GeoVax Labs New news (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs New stock.
GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company specializing in the development of human vaccines and immunotherapies against infectious diseases and cancers. Utilizing their innovative Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) platform, GeoVax has a strong focus on creating vaccines that stimulate both humoral and cellular immune responses to various targeted infections.
GeoVax's product pipeline includes an advanced Covid-19 vaccine, GEO-CM04S1, which is currently undergoing three phase 2 clinical trials. This next-generation vaccine is designed to induce robust antibody and T-cell responses against multiple SARS-CoV-2 variants, including Delta and Omicron. GEO-CM04S1 is especially targeted at high-risk immunocompromised populations who may not respond adequately to existing vaccines.
In oncology, GeoVax is pioneering novel therapies with Gedeptin®, an oncolytic gene-directed therapy for solid tumors. Gedeptin® is in phase 1/2 clinical trials for advanced head and neck cancers, aiming to provide new treatment avenues for patients with limited options.
GeoVax has shown significant progress in vaccine development against other infectious diseases such as Mpox, smallpox, HIV, Zika, hemorrhagic fever viruses, and malaria. Their recent partnership with the National Institute of Allergy and Infectious Diseases (NIAID) has expanded their vaccine development license to include Mpox and smallpox, leveraging their MVA technology for broader immunological protection.
The company also focuses on intellectual property, holding over 115 granted or pending patents across 24 patent families. This robust IP portfolio enhances their competitive edge in the biopharmaceutical sector.
GeoVax's commitment to innovative research and scalable manufacturing solutions positions them as a key player in the fight against some of the world’s most threatening diseases. For more detailed information, visit their official website at www.geovax.com.
GeoVax Labs announced positive interim data from its Phase 2 clinical trial of GEO-CM04S1, a dual-antigen COVID-19 vaccine booster for chronic lymphocytic leukemia (CLL) patients. The Data Safety Monitoring Board's review showed that while the mRNA control arm failed to meet the primary endpoint, GeoVax's vaccine arm should continue enrollment. The study at City of Hope National Medical Center compares two injections of GEO-CM04S1 against an mRNA vaccine control. GEO-CM04S1 uses a modified vaccinia virus vector containing both Spike and Nucleocapsid antigens, potentially offering broader immune response and better protection for immunocompromised CLL patients who typically show insufficient responses to current COVID-19 vaccines.
GeoVax Labs reported its Q3 2024 financial results and business updates. The company recorded a net loss of $5.8 million ($0.91 per share) for Q3 2024, compared to $8.4 million in Q3 2023. Revenue from BARDA/RRPV Project NextGen was $2.8 million for Q3 2024. Key developments include progress in the GEO-CM04S1 BARDA Phase 2b trial, advancement of Gedeptin® towards Phase 2 clinical trials for head and neck cancer, and development of the GEO-MVA Mpox vaccine. The company reported cash balances of $8.6 million as of September 30, 2024.
GeoVax Labs (Nasdaq: GOVX) announced it will report its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. markets close. The biotechnology company, which develops immunotherapies and vaccines against cancers and infectious diseases, will host a conference call and webcast with Q&A at 4:30 PM ET. Management will provide a corporate update and discuss financial results. Participants can access the call through registration, and an audio webcast archive will be available on the company's website for at least 90 days following the event.
GeoVax Labs, a biotechnology company focused on vaccine and cancer immunotherapy development, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024 in New York. David Dodd, the company's Chairman & CEO, will be part of a panel discussion on innovative therapies for solid tumors at 12:30 pm ET.
The company's senior management will also be available for one-on-one meetings with registered attendees. Interested parties can arrange meetings through their ROTH representative or by contacting GeoVax directly at info@geovax.com.
This participation highlights GeoVax's commitment to advancing its research and development in the field of cancer immunotherapies and human vaccines.
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company focused on developing immunotherapies and vaccines, has announced its participation in two upcoming investor conferences in September 2024. Chairman and CEO David Dodd will present at both events:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET in New York, NY.
2. Emerging Growth Conference on September 25, 2024, at 2:55 p.m. ET, which will be held virtually.
Both presentations will provide corporate updates on GeoVax. At the H.C. Wainwright conference, senior management will also host one-on-one meetings with registered attendees. Interested parties can contact GeoVax directly at info@geovax.com to arrange meetings.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, has announced a registered direct offering priced at-the-market. The company will sell 975,610 shares of common stock (or equivalents) at $5.125 per share to an institutional investor. Additionally, in a concurrent private placement, GeoVax will issue warrants to purchase up to 975,610 shares at $5.00 per share, exercisable immediately with a five-year term.
The offering is expected to raise approximately $5.0 million in gross proceeds, before deducting fees and expenses. GeoVax plans to use the net proceeds for working capital and general corporate purposes. Roth Capital Partners is acting as the exclusive placement agent. The offering is anticipated to close around August 30, 2024, subject to customary closing conditions.
GeoVax Labs (Nasdaq: GOVX), a biotechnology company focused on developing immunotherapies and vaccines, has announced an upcoming webinar titled 'Now Is Not the Time to Monkey(pox) Around'. The event, scheduled for August 23, 2024, at 11:00am ET, will feature CEO David Dodd providing a detailed overview of Mpox, including insights on its rapid spread and methods for control, treatment, and prevention.
The webinar, hosted by Tribe Public , offers a complimentary registration for participants who can submit questions in advance or during the event. This presentation aims to address the growing concerns surrounding Mpox and highlight GeoVax Labs' potential role in combating the disease.
GeoVax Labs, Inc. (Nasdaq: GOVX) has announced a registered direct offering of 1,700,000 shares of common stock (or equivalents) at $5.00 per share, priced above-the-market. The biotechnology company is expected to raise approximately $8.5 million in gross proceeds. In a concurrent private placement, GeoVax will issue warrants to purchase up to 1,700,000 additional shares at $5.00 per share, exercisable immediately with a five-year term.
Roth Capital Partners is acting as the exclusive placement agent. The offering is expected to close around August 21, 2024. GeoVax intends to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to a previously filed and effective shelf registration statement.
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines, will present at the Emerging Growth Conference on August 21, 2024. Chairman and CEO David Dodd will deliver a live, interactive presentation at 4:10pm ET, discussing recent Mpox developments and milestones related to the BARDA Project NextGen Award for their next-generation COVID-19 vaccine.
The event offers shareholders and investors the opportunity to interact with Mr. Dodd in real-time. Attendees can submit questions in advance or during the event. Registration is required to attend and receive updates. For those unable to join live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.
GeoVax Labs, Inc. (Nasdaq: GOVX) has appointed Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Prof. Lambe, a renowned vaccinology and immunology expert from the Oxford Vaccine Group, was a key figure in developing the Oxford/AstraZeneca COVID-19 vaccine. Her research focuses on designing vaccination strategies based on post-infection immune responses. GeoVax's Chief Scientific Officer, Dr. Mark Newman, highlighted how Prof. Lambe's expertise aligns with their vaccine and immunotherapy programs, including the recent BARDA Project NextGen Award for next-generation COVID-19 vaccines. David Dodd, GeoVax's Chairman and CEO, emphasized the importance of Prof. Lambe's insights for advancing their clinical trials and bringing new therapies to market.
FAQ
What is the current stock price of GeoVax Labs New (GOVX)?
What is the market cap of GeoVax Labs New (GOVX)?
What is GeoVax Labs, Inc.?
What is the MVA-VLP platform?
What are the main products in GeoVax’s pipeline?
What is the current status of the GEO-CM04S1 vaccine?
What is Gedeptin®?
How does GeoVax’s partnership with NIAID benefit their technology?
What recent achievements has GeoVax announced?
How extensive is GeoVax’s intellectual property portfolio?
What is the significance of GeoVax’s Covid-19 vaccine?
How can I learn more about GeoVax Labs, Inc.?
